Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 10, Issue 4, Pages 547-561Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.14
Keywords
BBB; blood-cerebrospinal fluid barrier; central nervous system; cerebrospinal fluid; CNS; intra-cerebrospinal fluid; leptomeningeal; targeted therapies
Categories
Funding
- Enzon Pharmaceuticals, Inc
Ask authors/readers for more resources
Prolonged survival with targeted therapies has sometimes come at the expense of an increased risk of CNS relapse; because many of these agents poorly penetrate the BBB, malignant cells may remain viable within the CNS. The ability of anticancer drugs to penetrate the BBB is a major consideration in the treatment of CNS parenchymal metastases. Optimal chemotherapy approaches for treating CNS metastases remain unclear due to a lack of evidence-based recommendations. Recent hypothesis-generating studies evaluating intra-cerebrospinal fluid administration of targeted agents indicate that these drugs may be effective in treating leptomeningeal disease and are associated with a low incidence of drug-related adverse events. Newer strategies for treating cerebrospinal fluid metastases may co-opt endogenous systems of the BBB, such as those involved in receptor-mediated transcytosis or classic carrier-mediated transporter systems to facilitate drug delivery across the BBB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available